Elevation Financial Statements From 2010 to 2024

Stocks . USA . 
Stock . Elevation Oncology
ELEV Stock  USD 0.60  0.01  1.64%   
Elevation Oncology financial statements provide useful quarterly and yearly information to potential Elevation Oncology investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Elevation Oncology financial statements helps investors assess Elevation Oncology's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Elevation Oncology's valuation are summarized below:
Market Capitalization
35.7 M
Earnings Share
(0.80)
There are over one hundred four available fundamental signals for Elevation Oncology, which can be analyzed over time and compared to other ratios. All traders should should verify Elevation Oncology's prevailing fundamental trends against the trends from 2010 to 2024 to make sure the company is sustainable. Market Cap is likely to drop to about 20 M in 2024. Enterprise Value is likely to climb to about (894 K) in 2024
Check Elevation Oncology financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Elevation Oncology's main balance sheet or income statement drivers, such as Depreciation And Amortization of 37 K, Interest Expense of 4.4 M or Selling General Administrative of 9.2 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 0.35. Elevation financial statements analysis is a perfect complement when working with Elevation Oncology Valuation or Volatility modules.
  
Check out the analysis of Elevation Oncology Correlation against competitors.
For more information on how to buy Elevation Stock please use our How to Invest in Elevation Oncology guide.

Elevation Oncology Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets91.4 M89.1 M34.9 M
Slightly volatile
Other Current Liabilities3.8 M3.6 M1.5 M
Slightly volatile
Total Current Liabilities7.9 M4.1 M3.3 M
Slightly volatile
Accounts Payable481.6 K507 K1.6 M
Slightly volatile
Cash71 M49.3 M27.3 M
Slightly volatile
Cash And Short Term Investments88.2 M83.1 M33.6 M
Slightly volatile
Common Stock Shares Outstanding28.2 M34.1 M24.7 M
Slightly volatile
Liabilities And Stockholders Equity91.4 M89.1 M34.9 M
Slightly volatile
Non Current Liabilities Total26.2 M30.1 M17 M
Slightly volatile
Other Current Assets3.4 M4.9 M1.4 M
Slightly volatile
Total Liabilities32 M34.3 M20.1 M
Slightly volatile
Total Current Assets90.9 M88 M34.7 M
Slightly volatile
Net Working Capital83 M83.8 M31.5 M
Slightly volatile
Other Liabilities1.7 K1.8 K11.9 K
Slightly volatile
Non Currrent Assets Other619 K1.1 M234.6 K
Slightly volatile
Other Assets0.951.0122.2 K
Pretty Stable
Non Current Liabilities Other1.7 K1.8 K11.9 K
Slightly volatile
Intangible Assets69.0359.058.6687
Slightly volatile
Common Stock2.9 K4 K2.2 K
Slightly volatile
Property Plant Equipment74.8 K112.7 K49.4 K
Slightly volatile
Short and Long Term Debt Total32.8 M30.1 M29.7 M
Slightly volatile
Long Term Debt32.8 M30.1 M29.7 M
Slightly volatile
Common Stock Total Equity1.6 K1.8 K2 K
Slightly volatile
Long Term Debt Total23.5 M26.5 M28.8 M
Slightly volatile
Capital Surpluse159.6 M179.5 M195.5 M
Slightly volatile

Elevation Oncology Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization37 K39 K2.4 M
Slightly volatile
Selling General Administrative9.2 M14.9 M3.9 M
Slightly volatile
Selling And Marketing Expenses33.3 K35.1 K374.5 K
Slightly volatile
Other Operating Expenses42.9 M45.4 M19.4 M
Slightly volatile
Research Development32.7 M25.4 M15.3 M
Slightly volatile
Total Operating Expenses42.9 M45.4 M19.4 M
Slightly volatile
Cost Of Revenue27.2 K39 K18.4 K
Slightly volatile
Reconciled Depreciation27.2 K39 K18.4 K
Slightly volatile
Interest Income2.7 M3.9 M1.3 M
Slightly volatile

Elevation Oncology Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Net Borrowings23.9 M26.6 M29.3 M
Slightly volatile
Stock Based Compensation1.8 M3.3 M673.2 K
Slightly volatile
Depreciation25.7 K39 K20.3 K
Slightly volatile
Total Cash From Financing Activities59.8 M48 M26.4 M
Slightly volatile
End Period Cash Flow71 M49.3 M27.3 M
Slightly volatile
Change To Netincome4.2 M4 M898.6 K
Slightly volatile
Begin Period Cash Flow75.2 M45.9 M24.4 M
Slightly volatile
Issuance Of Capital Stock56.1 M41.9 M82.2 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Capex To Depreciation4.363.664.4305
Slightly volatile
Payables Turnover0.08080.07690.0129
Slightly volatile
Cash Per Share2.572.43881.2845
Slightly volatile
Days Payables Outstanding110.3 K98.9 K111.3 K
Slightly volatile
Income Quality0.751.22920.9198
Very volatile
Intangibles To Total Assets0.00.00.0
Pretty Stable
Net Debt To EBITDA0.440.4610.8803
Slightly volatile
Current Ratio22.2821.22177.3597
Slightly volatile
Graham Number6.366.96673.7793
Slightly volatile
Debt To Equity0.640.54990.5996
Very volatile
Capex Per Share0.00270.00330.0031
Slightly volatile
Interest Debt Per Share1.261.00671.2654
Slightly volatile
Debt To Assets0.260.33830.3108
Pretty Stable
Days Of Payables Outstanding110.3 K98.9 K111.3 K
Slightly volatile
Ebt Per Ebit0.81.0050.9869
Slightly volatile
Long Term Debt To Capitalization0.40.35480.3754
Very volatile
Total Debt To Capitalization0.40.35480.3754
Very volatile
Debt Equity Ratio0.640.54990.5996
Very volatile
Quick Ratio22.2821.22177.3597
Slightly volatile
Net Income Per E B T0.81.00070.9869
Slightly volatile
Cash Ratio7.3711.8835.3114
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.11.151.021
Slightly volatile
Debt Ratio0.260.33830.3108
Pretty Stable

Elevation Oncology Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap20 M21 M212.6 M
Slightly volatile

Elevation Fundamental Market Drivers

Cash And Short Term Investments83.1 M

Elevation Upcoming Events

14th of March 2024
Upcoming Quarterly Report
View
20th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
14th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Elevation Oncology Financial Statements

Elevation Oncology investors use historical fundamental indicators, such as Elevation Oncology's revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Elevation Oncology. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Cost Of Revenue39 K27.2 K

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Elevation Stock Analysis

When running Elevation Oncology's price analysis, check to measure Elevation Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Elevation Oncology is operating at the current time. Most of Elevation Oncology's value examination focuses on studying past and present price action to predict the probability of Elevation Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Elevation Oncology's price. Additionally, you may evaluate how the addition of Elevation Oncology to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY